Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombosis and Anticoagulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for F11 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | F11 Recombinant Protein (Zymogen & Active Form) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Available as Zymogen or Active (FXIa) Form. |
View F11 Products |
| Gene Delivery | F11 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and coagulation cascade reconstitution assays. |
View F11 Products |
| Benchmark Ab | Anti-F11 (Abelacimab/Osocimab Sequence) Recombinant positive control. Sequence Verified. |
View F11 Products |
| Validator | F11 siRNA Set For knockdown verification in hepatocyte models and functional assays. |
View F11 Products |
| Related Target F12 | F12 (Factor XII) Upstream contact activator; critical for FXI activation pathway studies. |
View F12 Products |
| Related Target F2 | F2 (Thrombin/Prothrombin) Downstream coagulation target; comparator for bleeding risk assays. |
View F2 Products |
| Related Target KLKB1 | KLKB1 (Plasma Kallikrein) Homology check for selective FXIa inhibitor screening. |
View KLKB1 Products |
| Related Target F10 | F10 (Factor X) Downstream convergence point; essential for selectivity counter-screening. |
View F10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Toxicology Evaluation | Human/Cyno/Mouse F11 ortholog proteins available with >95% purity; Sequence Verified for epitope conservation and seamless pre-clinical translation. |
| Zymogen vs Active Enzyme Selectivity | Native F11 (Zymogen) and FXIa (Active) preparations with confirmed theoretical MW and high purity for mechanistic binding studies. |
| Serine Protease Subfamily Counter-Screening (FXa, Thrombin, FXIIa, Kallikrein) | Homolog panel proteins (F10, F2, F12, KLKB1) strictly verified by mass spec for robust off-target profiling. |
| Lack of Reliable Positive Controls | Clinical Benchmark Antibodies (Biosimilars of Abelacimab/Osocimab) included with Endotoxin Controlled specs; FXI-deficient plasma compatibility. |
| Cell-Based Assay False Positives | High-specificity siRNA included for baseline validation, knockdown checks, and RNAi rescue experiments. |
Live F11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for F11 (Coagulation Factor XI) therapeutics is intensifying, with major players shifting focus from traditional Factor Xa and Thrombin inhibitors to novel modalities targeting the intrinsic coagulation pathway. The central thesis of targeting F11 is the potential to decouple thrombosis (pathological clot formation) from hemostasis (normal bleeding control), offering a safer anticoagulation profile. As first-generation small molecules and monoclonal antibodies reach advanced clinical phases (e.g., Milvexian, Abelacimab, Osocimab), the next wave of R&D is targeting prolonged-action ASOs (Fesomersen) and bispecifics aimed at patients with end-stage renal disease (ESRD) or those requiring secondary stroke prevention where standard DOACs carry unacceptable bleeding risks. Future developments also include aptamer-based rapid reversal agents for acute interventions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | BMS/J&J (Milvexian), Bayer (Asundexian), Pfizer | Atrial Fibrillation, Stroke, VTE | Selectivity Assay (Need Sequence Verified F11, F10, F2, F12, KLKB1 proteins) |
| Monoclonal Antibody | Anthos Therapeutics (Abelacimab), Bayer (Osocimab) | ESRD, Cancer-associated VTE, Post-surgical VTE | Affinity & Cross-species Binding (Need High-Purity Cyno/Human F11 zymogen and active forms) |
| Antisense Oligo (ASO)/siRNA | Ionis Pharmaceuticals (Fesomersen), Silence Therapeutics | Severe Thrombophilia, Chronic thromboembolic prevention | In vitro Knockdown Validation (Need F11 ORF Lentivirus for stable cell lines and target standards) |
| Aptamer / Peptides | ARCA biopharma, various biotechs | Acute Hemodialysis, Acute intervention | Rapid Reversibility Screening (Need Native Glycosylation F11 proteins for binding studies) |